PEBP1 and urinary bladder carcinoma: Consistent with RIKP’s potential role in molecular events relevant to tumor suppression, RKIP downregulations, and RKIP’s associations with cancer progression, RKIP-derived tumor suppressive activities have been reported in multiple cancer types, including urogenital cancers (bladder cancer [84], clear cell renal cell carcinoma [85,86,87], and PC [88,89]), breast cancer [90], pancreatic cancer [91], hepatoma [92], non-small cell lung cancer [93], gastric cancer [94], and others [95].